Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate. Arcturus on Thursday said the designation ...

Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including mRNA, siRNA, replicon RNA, asRNA, DNA, and gene editing therapeutics.